In a phase I trial of CMG901—a first-in-class antibody–drug conjugate targeting claudin 18.2—researchers found that it can best current therapies for treating gastric and gastroesophageal cancers. Historically, progression-free survival (PFS) hovers around 7 months and overall survival (OS) around 14 to 16 months. However, depending on the dose, PFS with CMG901 ranged from 3.3 to 14.5 months, and OS ranged from 8.5 months to not reached, after a median follow up of 6 months.

You do not currently have access to this content.